Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency

Abstract Objective. The study was aimed to assess the effect of hydrocortisone (HC) replacement therapy on bone mineral density (BMD) and bone turnover markers in patients with primary adrenal insufficiency (PAI). Methods. A cross-sectional study was conducted in 37 PAI patients treated with HC. BMD and selected bone turnover markers (β-crosslaps and osteocalcin) were measured. A stepwise binary logistic regression model was applied to determine the independent variables associated with low BMD. Results. Osteoporosis was noted in 14.3% and osteopenia in 34.3% of cases. These patients were older (p=0.01) and received higher daily HC dose compared to patients with normal BMD (p=0.01). BMD values in the lumbar spine and the femoral neck were negatively correlated with daily HC dose (r=–0.36, p=0.03 and r=–0.34, p=0.05, respectively). Plasma osteocalcin was negatively correlated with disease duration (r=–0.38, p=0.02) and cumulative HC dose (r=–0.43, p<0.01). In multivariate analysis, a daily HC dose ≥12 mg/m2/day was independently associated with a higher risk of osteopenia/osteoporosis [OR (95% CI), 9.0 (1.1–74.6); p=0.04]. Conclusions. Impaired bone mineralization in patients with PAI is correlated with HC dose. A daily HC dose ≥12 mg/m2/day was associated with an increased risk of osteopenia and osteoporosis in these patients.

[1]  M. Terzolo,et al.  Effects on bone health of glucocorticoid replacement therapy in primary and secondary adrenal insufficiency: A review , 2018, Current Opinion in Endocrine and Metabolic Research.

[2]  A. Frigo,et al.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy , 2018, Endocrine.

[3]  F. Kanoun,et al.  Bone Mineral Density in Sheehan's Syndrome; Prevalence of Low Bone Mass and Associated Factors. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[4]  Stefan R Bornstein,et al.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[5]  M. Quinkler,et al.  Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  R. Civitelli,et al.  Bone turnover markers: understanding their value in clinical trials and clinical practice , 2009, Osteoporosis International.

[7]  F. Huppert,et al.  Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.

[8]  S. Hahner,et al.  Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements , 2006, Clinical endocrinology.

[9]  M. Feki,et al.  Vitamin D deficiency in Tunisia , 2005, Osteoporosis International.

[10]  G. Martínez,et al.  Long‐term follow‐up of bone mineral density in Addison's disease , 2003, Clinical endocrinology.

[11]  M. Fassnacht,et al.  Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. , 2001, The Journal of clinical endocrinology and metabolism.

[12]  I. Reid,et al.  Bone Mineral Density in Patients with Treated Addison’s Disease , 1999, Osteoporosis International.

[13]  R. Eastell,et al.  Glucocorticoid replacement therapy: are patients over treated and does it matter? , 1997, Clinical endocrinology.

[14]  P. V. van Rijk,et al.  Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison Disease , 1994, Annals of Internal Medicine.